APTBIO
Cutting-Edge Omics for Your Research.
Cutting-Edge Omics for Your Research.
APTBIO is a Hong Kong S.a.r. based biotechnology startup that aims to revolutionize the field of life sciences with its cutting-edge omics solutions. Founded in 2004, the company is committed to providing advanced multi-omics services by integrating AI big data with mass spectrometry platforms. INOMIXO's offerings include proteomics, peptidomics, metabolomics, spatial omics, and bioinformatics analysis for academic organizations, as well as customized CRO and CMC certification services for the biopharmaceutical industry. The company recently secured a Series B investment led by Legend Capital on 17 August 2022. With a dedicated team and a focus on innovation, APTBIO is poised to deliver robust and professional omics solutions for the advancement of life sciences.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | Unknown | 2 |
|
08 Apr 2024 |
| Series B | Unknown | 1 |
|
17 Aug 2022 |
| Series A | $28.29M | 3 |
|
23 Apr 2020 |
No recent news or press coverage available for APTBIO.
We care about your data, and we'd love to use cookies make your experience better.
